Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | P105_A106del |
Impact List | deletion |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 P105_A106del results in the deletion of two amino acids in the protein kinase domain of the Map2k1 protein from amino acids 105 to 106 (UniProt.org). P105_A106del results in increased phosphorylation of Mek and Erk relative to wild-type Map2k1 in cell culture (PMID: 30377225). |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 P105_A106del |
Transcript | NM_002755.4 |
gDNA | chr15:g.66436767_66436772delCCCGCA |
cDNA | c.313_318delCCCGCA |
Protein | p.P105_A106delPA |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017022411 | chr15:g.66436767_66436772delCCCGCA | c.313_318delCCCGCA | p.P105_A106delPA | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66436767_66436772delCCCGCA | c.313_318delCCCGCA | p.P105_A106delPA | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66436767_66436772delCCCGCA | c.313_318delCCCGCA | p.P105_A106delPA | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66436767_66436772delCCCGCA | c.313_318delCCCGCA | p.P105_A106delPA | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66436833_66436838delGTGGGC | c.313_318delGTGGGC | p.V105_G106delVG | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66436833_66436838delGTGGGC | c.313_318delGTGGGC | p.V105_G106delVG | RefSeq | GRCh38/hg38 |
XM_017022413 | chr15:g.66485138_66485143delGAGATG | c.314_319delGAGATG | p.G105_D106delGD | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66436767_66436772delCCCGCA | c.313_318delCCCGCA | p.P105_A106delPA | RefSeq | GRCh38/hg38 |
XM_011521783.3 | chr15:g.66436833_66436838delGTGGGC | c.313_318delGTGGGC | p.V105_G106delVG | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66436767_66436772delCCCGCA | c.313_318delCCCGCA | p.P105_A106delPA | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66436833_66436838delGTGGGC | c.313_318delGTGGGC | p.V105_G106delVG | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66436833_66436838delGTGGGC | c.313_318delGTGGGC | p.V105_G106delVG | RefSeq | GRCh38/hg38 |
XM_017022413.1 | chr15:g.66485138_66485143delGAGATG | c.314_319delGAGATG | p.G105_D106delGD | RefSeq | GRCh38/hg38 |
XM_011521783.4 | chr15:g.66436833_66436838delGTGGGC | c.313_318delGTGGGC | p.V105_G106delVG | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 mutant | Erdheim-Chester disease | sensitive | Cobimetinib | Guideline | Actionable | Cotellic (cobimetinib) is included in guidelines as preferred first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring mutations in the MAPK pathway such as ARAF, NRAS, KRAS, MAP2K1/2, PIK3CA, or with no detectable mutations, or for whom testing is not available (NCCN.org). | detail... |
MAP2K1 mutant | Erdheim-Chester disease | sensitive | Trametinib | Guideline | Actionable | Mekinist (trametinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring mutations in the MAPK pathway such as ARAF, NRAS, KRAS, MAP2K1/2, PIK3CA, or with no detectable mutations, or for whom testing is not available (NCCN.org). | detail... |